Answers are grounded in this paper and cite their sources.
Background Amyloid-related imaging abnormalities (ARIA), including ARIA-edema or effusion (E) and ARIA-hemorrhage (H), are the most common and important treatment-related adverse event of anti-amyloid-β immunotherapy. Real-world populations and clinical management may differ from randomized controlled trials. This study estimated the real-world incidence of ARIA in lecanemab-treated patients and to compare it by geographic region, MRI protocol, and APOE ε4 carrier status. Methods PubMed and Embase were searched for studies published through April 28, 2026. Real-world lecanemab studies in mild cognitive impairment due to Alzheimer disease or Alzheimer dementia reporting ARIA-E or H were included. The pooled incidences of ARIA and subgroup analyses by geographic region, MRI sequence, MRI magnet strength, and APOE ε4 status were calculated with a random-effects model; pooled ORs by APOE ε4 carrier status were also calculated. Results Twenty-one real-world studies were identified, analyzing data from 4,818 patients. Pooled incidence was 14.5% (95%CI: 11.8–17.7) for any ARIA, 5.5% (95%CI, 3.9–7.7) for ARIA-E, 11.5% (95%CI, 9.0–14.4) for ARIA-H. Symptomatic ARIA and severe ARIA occurred in 2.1% (95%CI, 1.4–3.2) and 1.3% (95%CI, 0.8–2.0), respectively, and isolated ARIA-H in 8.5% (95%CI, 6.5–11.0). The incidence of any ARIA varied by geographic region, the highest in the United States (21.6%) and lowest in Asia (12.9%) ( P =.003). Incidence of ARIA-E differed by MRI field strength ( P <.001), whereas incidence of ARIA-H did not differ by MRI sequence ( P =.09). APOE ε4 homozygotes had higher odds of ARIA-E than heterozygotes (OR,3.1; 95%CI, 1.7–5.7) and noncarriers (OR,3.3; 95%CI, 1.7–6.4) (both P <.001), and higher odds of ARIA-H than noncarriers (OR,2.4; 95% CI, 1.1–4.9; P =.02) but not heterozygotes (OR,1.9; 95% CI, 0.96–3.6; P =.07). Conclusion The real-world incidences of ARIA-E (5.5%) and H (11.5%) were lower than those in the Clarity AD trial (12.6% and 17.3%) and pooled phase 3 trials (9.5% and 17.8%). In real-world settings, incidence varied by geographic region (lowest in Asian cohorts), and MRI protocol, and the risk of ARIA-E increased with APOE ε4 gene dose, supporting standardized MRI surveillance and APOE ε4–informed risk stratification for the safe real-world use of lecanemab.
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: